Opuviz (Aflibercept)

Aflibercept acts as a decoy receptor that binds VEGF‑A, VEGF‑B and placental growth factor with high affinity. By sequestering these ligands, it blocks activation of VEGF receptors on retinal endothelial cells, inhibiting abnormal blood‑vessel growth and vascular leakage.

The dosing regimen for Opuviz is determined by the prescribing ophthalmologist based on the specific indication and patient response. The prescriber decides the volume to be injected and the interval between injections.

Safety data for aflibercept in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Opuviz product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Opuviz (aflibercept) has a broader binding profile, targeting VEGF‑A, VEGF‑B and placental growth factor, whereas some alternatives bind only VEGF‑A. Clinical studies suggest comparable efficacy in improving vision, with dosing intervals that may differ based on the specific condition and physician preference.

Opuviz should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until ready for use to maintain stability.

Opuviz is given as an intravitreal injection directly into the vitreous cavity of the eye. The procedure is performed by a qualified ophthalmologist in a sterile setting, using a fine‑gauge needle to deliver the prescribed volume.

Serious adverse events include endophthalmitis (severe eye infection), retinal detachment, significant intraocular inflammation, and rare systemic arterial thromboembolic events. Patients should be monitored closely for signs of infection, vision changes, or systemic vascular symptoms.

Opuviz is contraindicated in patients with active ocular infection at the injection site and should be used with caution in individuals with recent intraocular surgery, uncontrolled systemic vascular disease, or known hypersensitivity to aflibercept or any component of the formulation.